Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oripavine is a phenanthrene alkaloid naturally found in poppy plants such as Papaver bracteatum, Papaver orientale, and Papaver somniferum. It is an opioid and a major metabolite of thebaine. Although oripavine possesses analgesic potency comparable to morphine, it is not used clinically due to severe adverse effects, including tonic-clonic seizures, and a low therapeutic index. Its primary significance lies in its role as a key starting material (KSM) for the chemical synthesis of various potent semi-synthetic opioids, including opioid agonists (e.g., etorphine), partial agonists (e.g., buprenorphine), and opioid antagonists (e.g., naloxone, naltrexone). Due to its easy convertibility into other controlled substances, oripavine is itself a controlled substance in many jurisdictions globally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oripavine.